Suraksha Diagnostic Ltd
Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution.[1]
- Market Cap ₹ 2,000 Cr.
- Current Price ₹ 384
- High / Low ₹ 449 / 382
- Stock P/E 79.5
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 16.8 %
- ROE 15.2 %
- Face Value ₹ 2.00
Pros
Cons
- Promoter holding has decreased over last quarter: -23.6%
- Company has a low return on equity of 12.4% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 158 | 140 | 223 | 190 | 219 | |
| 123 | 115 | 175 | 143 | 146 | |
| Operating Profit | 34 | 25 | 48 | 47 | 73 |
| OPM % | 22% | 18% | 22% | 25% | 33% |
| 2 | -1 | 2 | 1 | 1 | |
| Interest | 2 | 2 | 2 | 10 | 10 |
| Depreciation | 13 | 16 | 15 | 32 | 33 |
| Profit before tax | 21 | 6 | 33 | 7 | 31 |
| Tax % | 28% | -1% | 28% | 10% | 26% |
| 15 | 6 | 24 | 6 | 23 | |
| EPS in Rs | 220.43 | 93.33 | 344.20 | 94.49 | 342.46 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 16% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 46% |
| TTM: | 248% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 12% |
| Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 9 |
| Reserves | 111 | 118 | 141 | 147 | 171 | 189 |
| 13 | 18 | 21 | 99 | 92 | 85 | |
| 42 | 28 | 32 | 28 | 30 | 37 | |
| Total Liabilities | 173 | 171 | 201 | 281 | 300 | 320 |
| 128 | 119 | 119 | 195 | 212 | 211 | |
| CWIP | 0 | 0 | 1 | 2 | 1 | 5 |
| Investments | 5 | 5 | 0 | 0 | 0 | 0 |
| 39 | 46 | 80 | 84 | 87 | 104 | |
| Total Assets | 173 | 171 | 201 | 281 | 300 | 320 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 31 | 24 | 42 | 44 | 60 | |
| -20 | -28 | -44 | -21 | -35 | |
| -10 | 3 | 1 | -24 | -25 | |
| Net Cash Flow | 1 | -1 | -0 | -1 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Debtor Days | 14 | 16 | 12 | 9 | 15 |
| Inventory Days | 93 | 62 | 38 | 82 | 89 |
| Days Payable | 227 | 177 | 84 | 187 | 193 |
| Cash Conversion Cycle | -120 | -99 | -34 | -96 | -89 |
| Working Capital Days | -35 | -2 | -4 | -17 | -12 |
| ROCE % | 8% | 23% | 9% | 17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
1d - Outcome of Analyst/Institutional Investor Meet.
-
Closure of Trading Window
1d - Closure of trading window until financial results announcement.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
23 Dec - Audio recording of Q2 FY25 earnings call available.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
21 Dec - Revised investor presentation for Q2 & H1 FY25 results.
-
Regulation 47 Of SEBI (LODR 2015- Newspaper Publications
21 Dec - Newspaper publication of unaudited financial results.
Business Model[1][2]
a) Integrated Services: Offers a one-stop solution for pathology, radiology, and medical consultancy services.
b) Comprehensive Testing: Provides 2,300+ diagnostic tests, ranging from routine pathology to advanced radiology.
c) Hub and Spoke Model: Operates through a central reference lab, 8 satellite labs, and a network of diagnostic and collection centers for efficient sample processing and service delivery.
d) Omni-channel Consultation: Combines online and offline medical consultation services, leveraging its polyclinics with 750+ doctors.
e) B2C-Focused Revenue Model: Primarily serves individual patients, with some revenue from B2B contracts.
Diagnostic Test Data[1][3]
a) Pathology Tests:
788 Routine Tests: Basic biochemistry, hematology.
664 Specialized Tests: Advanced biochemistry, histopathology, molecular pathology.
b) Radiology Tests:
766 Basic/Intermediate Tests: X-rays, USG, CT scans.
119 Advanced Tests: MRI scans, specialized CT scans.
Equipment: 24 CT and 13 MRI machines.
c) Testing Volume:
Q1 FY25: 1.58 million tests (0.28 million patients).
FY24: 5.98 million tests (1.14 million patients).
Geographical Presence [4]
West Bengal is their core market accounting for 95.34% of Q1 FY25 revenue. It also has a presence across Bihar, Assam, and Meghalaya. As of FY24, the company has a 1.15-1.3% market share in eastern India.